<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862268</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.395</article-id><article-id pub-id-type="other">EPP0192</article-id><article-id pub-id-type="pii">S092493382400395X</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Transcranial Magnetic Stimulation and its Efficacy in Alleviating Depressive Symptoms in Patients with Suicidal Ideation</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Moleon</surname><given-names>A.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor0256" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n-Bejarano</surname><given-names>M.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Alvarez de Toledo</surname><given-names>P.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Perez</surname><given-names>I.</given-names></name><xref rid="aff0819" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Narbona</surname><given-names>J.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Ferriol</surname><given-names>M.</given-names></name><xref rid="aff0819" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Perea</surname><given-names>R.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Oropesa</surname><given-names>J. M.</given-names></name><xref rid="aff0818" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Torres</surname><given-names>J.</given-names></name><xref rid="aff0819" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="aff0818"><sup>1</sup><institution>Instituto Andaluz de Salud Cerebral (IASC)</institution>, <city>Sevilla</city></aff><aff id="aff0819"><sup>2</sup><institution>Instituto Andaluz de Salud Cerebral (IASC)</institution>, <city>Huelva</city>, <country>Spain</country></aff><author-notes><corresp id="cor0256"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="370">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S181</fpage><lpage>S181</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S092493382400395Xa.pdf"/><abstract><sec id="sec1536"><title>Introduction</title><p>Suicide is a global public health issue. According to the latest available data from the National Institute of Statistics, 4,003 people died by suicide in 2021, reaching a new historical high. Approximately 90% of suicide victims suffer from one or more severe psychiatric disorders, and there is a documented 20-fold higher risk of suicide in individuals with affective disorders compared to healthy subjects (Abdelnaim et al., 2020). Repetitive transcranial magnetic stimulation (rTMS) has been established as an effective alternative or complementary treatment option for patients with depressive disorders, but little is known about its effects on suicide risk.</p></sec><sec id="sec1537"><title>Objectives</title><p>To assess the efficacy of rTMS in reducing depressive symptoms in patients with suicidal ideation and behaviors.</p></sec><sec id="sec1538"><title>Methods</title><p>Population and Methods: A retrospective analysis was conducted on a sample of 28 psychiatric patients (23 females; mean age 49.36 &#x000b1; 16.23) with suicidal ideation identified by item 3 (suicidality) of the Hamilton Depression Rating Scale (HDRS), who were treated with rTMS. All patients received a minimum of 30 sessions, consisting of the application of a high-frequency (&#x0003e;10Hz) or intermittent theta burst stimulation (TBS) over the left dorsolateral prefrontal cortex (DLPFC) at an intensity of 120% of the resting motor threshold (RMT), and repeated low-frequency pulses (1Hz) or continuous TBS over the right DLPFC with an intensity of 110% of the RMT.</p></sec><sec id="sec1539"><title>Results</title><p>Results: The results show a statistically significant improvement in depressive symptoms following rTMS intervention (p &#x0003c; 0.001). Furthermore, remission was observed in 46% of the sample (HDRS &#x0003c; 8).</p></sec><sec id="sec1540"><title>Conclusions</title><p>Discussion: In line with recent studies (Abdelnaim et al., 2020; Hines et al., 2022) and systematic reviews (Cui et al., 2022; Bozzay et al., 2020) on suicidal ideation in the context of psychiatric disorders, the findings of this study demonstrated that rTMS achieved satisfactory results in reducing depressive symptoms and suicidal ideation.</p><p>Conclusions: This clinical study indicates preliminary promise for the prevention of suicidal acts and underscores the need for more detailed and specific research on rTMS in the field of suicide.</p><p>Keywords: rTMS, neuromodulation, depression, suicide.</p></sec><sec id="sec1541"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>